Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Syndrome

Background:

• Cardiovascular disease (CVD) risk in type 2 diabetes (T2DM) is incompletely mitigated by glycemic control alone.
• Diabetic dyslipidemia and prolonged postprandial hyperlipidemia significantly contribute to CVD risk in T2DM.
• Postprandial lipid metabolism impacts endothelial function and predicts atherosclerosis.

Purpose of the Study:

• To review the role of postprandial lipid metabolism in endothelial dysfunction and CVD risk.
• To examine the capacity of incretins to modulate postprandial hyperlipidemia.
• To discuss the potential of incretin-based therapies in improving vascular function and reducing CVD risk in T2DM.

Main Methods:

• Literature review focusing on postprandial metabolism, incretin hormones, and cardiovascular outcomes.
• Analysis of current data on incretin-based medications and their effects on lipid profiles and vascular function.
• Synthesis of evidence regarding the therapeutic potential of incretins for CVD risk reduction in T2DM.

Main Results:

• Postprandial hyperlipidemia, driven by carbohydrate and lipid metabolism, promotes proatherogenic products and impairs endothelial function.
• Incretin hormones play a key role in regulating postprandial metabolic state.
• Incretin-based medications demonstrate potential to favorably influence postprandial lipid metabolism and cardiovascular functions.

Conclusions:

• Postprandial dyslipidemia is a critical, often overlooked, contributor to CVD risk in T2DM.
• Incretin-based therapies offer a novel strategy to address postprandial metabolic dysfunction.
• Targeting postprandial lipid metabolism with incretins may improve vascular health and reduce cardiovascular events in T2DM patients.